Response to the Second TNF-α Inhibitor (Adalimumab or Infliximab) after Failing the First One in Refractory Idiopathic Inflammatory Retinal Vascular Leakage

References

• Paovic J, Paovic P, Vukosavljevic M. Clinical and immunological features of retinal vasculitis in systemic diseases. Vojnosanit Pregl Mil-Med Pharmv Rev. 2009;66(12):961–965. doi:10.2298/VSP0912961P.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Ku J, Ali A, et al. Patients with retinal vasculitis rarely suffer from systemic vasculitis. Semin Arthritis Rheum. 2012;41(6):859–865. doi:10.1016/j.semarthrit.2011.10.006.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Sibley CH, Lin P. Retinal vasculitis. Curr Opin Rheumatol. 2016;28(3):228–235. doi:10.1097/BOR.0000000000000271.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee (2008) EULAR recommendations for the management of the Behcet disease. Ann Rheum Dis. 2008;67(12):1656–1662. doi:10.1136/ard.2007.080432.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Sharma PK, Markov GT, Bajwa A, Foster CS. Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis. Retina. 2015;35(12):2641–2646.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol. 2018;37(10):2805–2809.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019;38(2):407–415. doi:10.1007/s10067-018-4228-6.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol. 2018;37(10):2805–2809. doi:10.1007/s10067-018-4133-z.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). 2009;23(9):1868–1870. doi:10.1038/eye.2009.203.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Maleki A, Sahawneh HF, Ma L, et al. Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina. 2017;37(5):836–843. doi:10.1097/IAE.0000000000001269.
   PubMed Web of Science ®Google Scholar
• Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008;146:845–850. doi:10.1016/j.ajo.2008.09.010.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53(12):2223–2231. doi:10.1093/rheumatology/keu266.
   PubMed Web of Science ®Google Scholar
• Sharma PK, Markov GT, Bajwa A, Foster CS. Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis. Retina. 2015;35:2641–2646. doi:10.1097/IAE.0000000000000624.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016;68:1522–1530. doi:10.1002/art.39667.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74. doi:10.1016/j.jaut.2015.06.005.
   PubMed Web of Science ®Google Scholar
• Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85–95. doi:10.1038/nri724.
   PubMed Web of Science ®Google Scholar
• Anderlugt CL, Begolka WS, Neville KL, et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev. 1998;164:63–72. doi:10.1111/j.1600-065X.1998.tb01208.x.
   PubMed Web of Science ®Google Scholar
• Lejoyeux R, Diwo E, Vallet H, et al. Infliximab and adalimumab in uveitic macular edema. Ocul Immunol Inflamm. 2018;26(7):991–996. doi:10.1080/09273948.2018.1498110.
   PubMed Web of Science ®Google Scholar
• Cecchin V, Zannin ME, Ferrari D, et al. Long-term safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2018;45(8):1167–1172. doi:10.3899/jrheum.171006.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104–109. doi:10.1136/annrheumdis-2012-201445.
   PubMed Web of Science ®Google Scholar
• van Schie KA, Hart MH, de Groot ER, et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis. 2015;74(1):311–314. doi:10.1136/annrheumdis-2014-206237.
   PubMed Web of Science ®Google Scholar
• van Schouwenburg PA, Kruithof S, Votsmeier C, et al. Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies. J Biol Chem. 2014;289(50):34482–34488. doi:10.1074/jbc.M114.615500.
   PubMed Web of Science ®Google Scholar